SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    E. V. Filatova, A. Kh. Alieva, M. I. Shadrina, M. V. Shulskaya, E. Yu. Fedotova, S. N. Illarioshkin, S. A. Limborska, P. A. Slominsky, Analysis of mutations in patients with suspected autosomal dominant forms of Parkinson’s disease, Molecular Genetics, Microbiology and Virology, 2014, 29, 1, 1

    CrossRef

  2. 2
    Karen Nuytemans, Jessie Theuns, Marc Cruts, Christine Van Broeckhoven, Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update, Human Mutation, 2010, 31, 7
  3. 3
    L. Correia Guedes, J.J. Ferreira, M.M. Rosa, M. Coelho, V. Bonifati, C. Sampaio, Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: A systematic review, Parkinsonism & Related Disorders, 2010, 16, 4, 237

    CrossRef

  4. 4
    M.I. Shadrina, P.A. Slominsky, S.A. Limborska, 2010,

    CrossRef

  5. 5
    Seyedmehdi Shojaee, Farzad Sina, Niloofar Farboodi, Zeinab Fazlali, Farzaneh Ghazavi, Seyed Ali Ghorashi, Khosro Parsa, Homa Sadeghi, Gholam-Ali Shahidi, Mostafa Ronaghi, Elahe Elahi, A clinic-based screening of mutations in exons 31, 34, 35, 41, and 48 of LRRK2 in Iranian Parkinson's disease patients, Movement Disorders, 2009, 24, 7
  6. 6
    Avner Thaler, Elissa Ash, Ziv Gan-Or, Avi Orr-Urtreger, Nir Giladi, The LRRK2 G2019S mutation as the cause of Parkinson’s disease in Ashkenazi Jews, Journal of Neural Transmission, 2009, 116, 11, 1473

    CrossRef

  7. 7
    M. I. Shadrina, P. A. Slominsky, Mitochondrial dysfunction and oxidative damage in the molecular pathology of Parkinson’s disease, Molecular Biology, 2008, 42, 5, 720

    CrossRef

  8. 8
    S. N. Pchelina, A. F. Yakimovskii, A. K. Emelyanov, O. N. Ivanova, A. L. Schwarzman, A. B. Singleton, Screening for LRRK2 mutations in patients with Parkinson’s disease in Russia: identification of a novel LRRK2 variant, European Journal of Neurology, 2008, 15, 7